DUBLIN, Nov. 4, 2015 /PRNewswire/ -- Allergan plc. (NYSE: AGN), a leading global pharmaceutical company today announced that 6 poster presentations for two investigational medications Rapastinel (GLYX-13 and NRX-1074 were presented at the Society for Neuroscience (SfN) Annual Meeting in Chicago, October 17 – 21, 2015.
The titles of the poster presentations were as follows:
- Suppression of spreading depolarization and stabilization of dendritic spines by rapastinel (GLYX-13), an NMDA receptor glycine-site functional partial agonist.
- Acute GLYX-13 (rapastinel) ameliorates acute ketamine and subchronic ketamine-and phencyclidine-induced memory deficits in C57BL/6J mice.
- Rapastinel (GLYX-13), an N-methyl-D-aspartate functional glycine site partial agonist, is efficacious in rat surgical models of neuropathic pain.
- Rapastinel (GLYX-13), an allosteric NMDA receptor modulator, exerts its antidepressant effects by acting at a novel NMDA receptor binding site.
- NRX-1074, an NMDA receptor modulator with glycine site partial agonist properties, induces rapid and long-lasting antidepressant-like effects in rats.
- GLYX13 increases mTORC1 signaling and synaptogenesis in the prefrontal cortex.
About rapastinel (GLYX-13) and NRX-1074 (AGN-241660)
Rapastinel (GLYX-13) is an investigational intravenous formulation of a novel NMDA receptor partial agonist, which is being evaluated for adjunctive treatment of MDD, and has shown a rapid onset of antidepressant efficacy 1 day after a single dose in a Phase 2 clinical trial of patients with MDD who had an inadequate response to one or more antidepressants. No psychotomimetic or hallucinogenic side effects were observed with rapastinel. A series of Phase 3 registration trials are planned to begin in 2016.
NRX-1074 is an investigational orally available derivative of rapastinel that is entering Phase 2 as a monotherapy treatment for adults with MDD. An intravenous formulation of NRX-1074 has previously shown a rapid antidepressant efficacy in an initial single-dose Phase 2 study in patients with MDD. Proof of concept studies of NRX-1074 are planned for the first half of 2016.
In August 2015, Allergan completed the acquisition of Naurex, a clinical stage biopharmaceutical company developing rapastinel and NRX-1074.
About Major Depressive Disorder (MDD)
Approximately 16 million Americans are living with Major Depressive Disorder (MDD). There remains a significant unmet need in treating MDD. Upwards of 70% of patients with (MDD) are partial or non-responders to first-line therapies which include SSRIs and SNRIs. Additionally, the STAR*D trial reported that only 33% of patients reported remission of their MDD symptoms after monotherapy with an SSRI. In patients that do respond to an SSRI, numerous clinical trials have shown that it can take anywhere from 2 to 6 weeks for a patient perceive and report that their depressive symptoms are improving. During these first 2 to 6 weeks of traditional monoamine-based therapy, patients may continue to experience significant depressive symptoms, which can include suicidal ideation in patients with severe, recurrent, or chronic depression.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE Allergan plc